Home Neurological Disorders ALS Triple Threat: NeuroSense Targets ALS

conf room — NeuroSense Therapeutics has enrolled the first patient in its Phase IIb PARADIGM trial (NCT05357950), assessing PrimeC’s safety, tolerability, and efficacy in people living with ALS. NeuroSense expects to complete enrollment in PARADIGM by year’s end, with topline results set to be reported in the second quarter of 2023. [NeuroSense Therapeutics]

Triple Threat: NeuroSense Targets ALS

First patients enrolled in Phase IIb trial of PrimeC, whose three mechanisms of action target deadly Lou Gehrig’s disease.

By Alex Philippidis

June 20, 2022

NeuroSense Therapeutics has enrolled the first patient in its Phase IIb PARADIGM trial (NCT05357950), assessing PrimeC’s safety, tolerability, and efficacy in people living with ALS. NeuroSense expects to complete enrollment in PARADIGM by year’s end, with topline results set to be reported in the second quarter of 2023. [NeuroSense Therapeutics]

By mitigating the degeneration and inflammatory response of motor neurons, NeuroSense reasons, PrimeC can improve motor performance, and recover the morphology of motor neurons, neuromuscular junction structures, and microglial cells—results first seen in preclinical studies in zebrafish models of ALS. Last year, NeuroSense reported positive results from its Phase IIa NST002 trial (NCT04165850) showing that PrimeC was both safe and tolerable in 15 ALS patients studied over 12 months . . .